Drug discovery system for
new drug-target combinations
Drug
discovery
system for
new
drug&target
combinations

For accelerating the identification of disease cause
and a proven track record of new therapeutics


From Genetic disease without treatment or unknown MOA
to precision medicine for populations and address patent cliffs
QRGenetics develop a powerful AI-supported drug discovery engine
that utilizes exclusive spatial analytics and proprietary datasets,
to rapidly discover novel drug-target combinations
prompting new applications for soon-expired drugs

From Genetic disease without treatment/unknown MOA
to precision medicine for populations address patent cliffs
QRGenetics develop AI drug-discovery engine
utilizes exclusive analytics & datasets,
to rapidly discover novel drug-target
prompting new applications for soon-expired drugs

Our Unique Discovery Process

Consolidate
Medical
data
Disease
data
Proprietary
database
Proprietary
Algorithms
Disease
Modeling
Protein
Modeling
Target
Identification
Drug
Discovery
Validate
Rapid clinical validation through preclinical tests, & in-human trials
Expand
Proprietary
Algorithms
AI-driven Data processing to locate prevalent diseases with spatially similar functional disorders
Power
Create a vast library of validated drug + target combinations, ready for clinical trials

Our Discovery Edge

Expanding Indications

extend the impact of our treatments, benefiting a broader range of patients
Rapid Target & Drug Identification

Accelerating from years
to months
New Market Demand

for shelf products, developed drugs and patented drugs

From Genetic Disease to Heart Failure

Genetic Indication

QRGenetics discover disease cause and treatment
Patients diagnose with a genetic disease caused by a point mutation that impacted blood supply to multiple organs and affect growth and development

Matching treatment

FDA-approved drug was matched and tested in a pre-clinical trial
Based on the results, an IND was submitted and a multicentre clinical trial was initiated

Drug Indication
Expansion

Same drug was also found beneficial for
1,000,000
patients that suffers from heart failure

Pipeline

Drug
program
Indication
type
Indication
name
Pre-clinical trial
Results
Clinical partner research
Clinical trial

QR-100
original
common
Neurodevelopmental disorder (NDPLH)
Autism Spectrum Disorder (ASD)
QR-755
original
Common
Common
Celiac Disease
Rheumatoid Arthritis (RA)
Inflammatory Bowel Disease (IBD)
QR-172
original
Common
Common
Common
Smooth Muscle Disease (MSMDS)
Heart failure
Abdominal and aortic Aneurysm
Myopathy
QR-9477
original
Common
to be disclosed
Obesity
QR-1355
original
Common
to be disclosed
PKD1

Management Team

Dr. Shane Wald Altman. Ph.D.

Co-Founder & CEO

Prof. Miguel Weil, Ph.D.

Co-Founder & Scientific advisor

Dan Lavi

Co-Founder, Entrepreneur
& Business Management

Dr. Noa Bielopolski, Ph.D.

Director of Science

Advisory Board

Ido Gonen

Board Member and
Business development
consultant

Dr. Dan Goldstaub

Board member
and Pharma consultant

Prof. Arnold Levine

Board Member and
Cancer research specialist

Prof. Hagit Baris Feldman

Genetic advisor

Contact us

A. Rokach Blvd 97, Tel Aviv-Yafo